Ronald W. Chapman II, chair of Chapman Law Group’s White Collar Defense & Government Investigations practice group, will be speaking on controlled substance compliance plans and preparing for DEA inspections at an upcoming virtual conference.
The American Conference Institute’s “Controlled Substances: Regulation, Litigation, and Enforcement,” which is set for July 20-22, 2020, is an annual forum on the latest regulatory and legal developments in the controlled substance industry. The conference is for pharmaceutical stakeholders and healthcare attorneys, and it includes updates from the DOJ, FDA and DEA on state and federal enforcement initiatives.
On July 20, Chapman will lead the “Compliance Think Tank: Building and Enhancing an Effective Controlled Substances Compliance Program” workshop. In the seminar, Chapman will explain the best practices for designing a comprehensive handbook on the latest regulatory developments that influence risk management, how to maintain compliance, and avoiding unforeseen fines and/or federal charges.
Then, on July 21, Chapman is a featured panelist for “DEA Site Visit Checklist: Tailoring Inspection Strategies for Every Link of the Supply Chain.” The discussion will examine procedures, inventory control concerns, recordkeeping, and security requirements for unannounced DEA visits to manufacturer, distributor and retail pharmacy sites.
Chapman’s national criminal law practice includes representing physicians, pain management specialists, and pharmacists in healthcare fraud, DEA compliance, and drug trafficking matters. He is regularly invited by state and national medical societies and criminal defense organizations to serve as an expert at seminars on Medicare and Medicaid fraud, unlawful prescribing, and government investigations.